The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...

NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, ...

Shares of Novavax Inc. NVAX slid 6.10% to $8.46 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.09% to 19,281.40 ...

Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...

Novavax stock fell sharply after the pharmaceutical company cut its forecast for annual revenue despite better-than-expected ...

Nvidia share price gained 2.1%, while Amazon and Microsoft shares rose over 1% each. Amgen stock price tanked 7%, Novavax ...

US stocks were muted on Tuesday as investors were awaiting the key economic data such as inflation and retail sales due later ...

In a report released yesterday, Alec Stranahan from Bank of America Securities reiterated a Buy rating on Springworks Therapeutics (SWTX ...

December S&P 500 E-Mini futures (ESZ24) are down -0.09%, and December Nasdaq 100 E-Mini futures (NQZ24) are down -0.14% this morning as investors assessed the potential policy impact of Donald Trump’s ...

December S&P 500 E-Mini futures (ESZ24) are trending down -0.19% this morning as investors held back from making big bets ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...